Drug discovery and development company ImmuPharma plc (LSE:IMM) said on Monday that its US partner, Avion Pharmaceuticals, is seeking final regulatory guidance from the US Food and Drug Administration (FDA) as it prepares for the start of the international Phase 3 trial of Lupuzor, a first-in class autophagy immunomodulator, in lupus patients.
Lupus (Systemic Lupus Erythematosus or SLE) is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs.
Avion has submitted positive results from the Lupuzor/P140 pharmacokinetic study to the FDA. This study met all the key endpoints and (in line with all human dosing to date) demonstrated that the treatment was safe and well tolerated across all doses and in all subjects.
As part of the licence and development agreement for Lupuzor entered into between Avion and ImmuPharma, the new international Phase 3 trial is being funded by Avion, which has the exclusive rights to commercialise Lupuzor in the US. The rest of the world rights remain with ImmuPharma.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial